Determination of ZAP70 expression as a prognostic marker of chronic lymphocytic leukemia
DOI:
https://doi.org/10.15587/2519-4798.2019.179628Keywords:
chronic lymphocytic leukemia, ZAP70, prognostic marker, stage of the disease, treatment, survivalAbstract
Chronic lymphocytic leukemia (CLL) is a clinically and biologically heterogeneous disease. Some patients live for decades without any therapy, others die several years after diagnosis, despite the use of different lines of therapy. Significant progress has been achieved in the study of the pathogenesis of CLL, but over the past two decades there has been an intensive search for new biomarkers that may include a prognosis and also decide on therapeutic tactics. In conditions where complex genetic studies are expensive and inaccessible for routine analysis, the determination of ZAP70 remains relevant and sufficiently accessible to predict the course of CLL.
Aim of the research: to evaluate the prognostic significance of the level of expression of ZAP70 and its dependence on the stage of the disease in patients with chronic lymphocytic leukemia.
Materials and methods: under our supervision, there were 68 patients with chronic lymphocytic leukemia at various stages of the disease, among them 24 women aged 40-84 years (median 65 years) and 44 men aged 43-84 years (median 63 years). 51 patients received adequate treatment. Immunophenotypic studies of the lymphoid cell population and ZAP70 were performed using flow cytometry.
Results of the research: indicators of expression of ZAP70 in patients at different stages of the disease did not differ significantly. Overall survival in the group of patients with ZAP70 expression <20% was significantly higher compared with patients with ZAP70 expression >20%.
Conclusions: in CLL patients, the level of expression of ZAP70 is stable, does not depend on the stage of the disease, and does not change during the progression of the disease. ZAP70 expression level >20% of cells is a poor prognostic marker of the course of the disease and indicates a high risk of the disease.
References
- Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H. et. al. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131 (25), 2745–2760. doi: http://doi.org/10.1182/blood-2017-09-806398
- Truger, M. S., Jeromin, S., Weissmann, S., Dicker, F., Kern, W., Schnittger, S. et. al. (2014). Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia. British Journal of Haematology, 168 (1), 153–156. doi: http://doi.org/10.1111/bjh.13077
- Gribben, J. (2014). Prognostic and predictive factors in chronic lymphocytic leukemia. EHA Learning Center Hematology Education, 8 (1), 59–74.
- Shindiapina, P., Brown, J. R., Danilov, A. V. (2014). A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects inTP53. British Journal of Haematology, 167 (2), 149–161. doi: http://doi.org/10.1111/bjh.13042
- Cortese, D., Sutton, L.-A., Cahill, N., Smedby, K. E., Geisler, C., Gunnarsson, R. et. al. (2013). On the way towards a “CLL prognostic index”: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia, 28 (3), 710–713. doi: http://doi.org/10.1038/leu.2013.333
- Gaidano, G., Rossi, D. (2017). The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology, 2017 (1), 329–337. doi: http://doi.org/10.1182/asheducation-2017.1.329
- Sagatys, E. M., Zhang, L. (2012). Clinical and Laboratory Prognostic Indicators in Chronic Lymphocytic Leukemia. Cancer Control, 19 (1), 18–25. doi: http://doi.org/10.1177/107327481201900103
- Berquet, L., Valleron, W., Grgurevic, S., Quelen, C., Zaki, O., Quillet-Mary, A. et. al. (2015). Small nucleolar RNA expression profiles refine the prognostic impact ofIGHVmutational status on treatment-free survival in chronic lymphocytic leukaemia. British Journal of Haematology, 172 (5), 819–823. doi: http://doi.org/10.1111/bjh.13544
- Pede, V., Rombout, A., Vermeire, J., Naessens, E., Vanderstraeten, H., Philippé, J., Verhasselt, B. (2013). Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-κB signalling. British Journal of Haematology, 163 (5), 621–630. doi: http://doi.org/10.1111/bjh.12588
- Del Principe, M., Del Poeta, G., Buccisano, F. et. al. (2006). Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 108 (3), 853–861. doi: http://doi.org/10.1182/blood-2005-12-4986
- Vroblova, V., Smolej, L., Krejsek, J. (2012). Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia. Hematology, 17 (5), 268–274. doi: http://doi.org/10.1179/1607845412y.0000000015
- Deaglio, S., Vaisitti, T., Serra, S., Audrito, V., Bologna, C., D’Arena, G. et. al. (2011). CD38 in Chronic Lymphocytic Leukemia: From Bench to Bedside? Mini-Reviews in Medicinal Chemistry, 11 (6), 503–507. doi: http://doi.org/10.2174/138955711795843338
- Späti, B., Child, J. A., Kerruish, S. M., Cooper, E. H. (1980). Behaviour of Serum β2-Microglobulin and Acute Phase Reactant Proteins in Chronic Lymphocytic Leukaemia. Acta Haematologica, 64 (2), 79–86. doi: http://doi.org/10.1159/000207215
- Vigovska, O. Ia. (2017). Determination of β2–microglobulin level as a prognostic marker of chronic lymphocytic leukemia. ScienceRise: Medical Science, 1 (9), 35–39. doi: http://doi.org/10.15587/2519-4798.2017.91280
- Poulain, S., Benard, C., Daudignon, A., Le Baron, F., Morel, P., Duthilleul, P. (2007). Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia? Leukemia & Lymphoma, 48 (6), 1219–1221. doi: http://doi.org/10.1080/10428190701286488
- Soumerai, J. D., Ni, A., Darif, M., Londhe, A., Xing, G., Mun, Y. et. al. (2019). Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. The Lancet Haematology, 6 (7), e366–e374. doi: http://doi.org/10.1016/s2352-3026(19)30085-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Olga Vygovska, Nataliya Pelenyo, Ivan Dzis, Tetiana Horodyska, Olha Boyko, Larysa Schevchenko
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
